Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

L1000 comparisons #495

Open
Zethson opened this issue Jan 9, 2024 · 0 comments
Open

L1000 comparisons #495

Zethson opened this issue Jan 9, 2024 · 0 comments
Labels
enhancement New feature or request

Comments

@Zethson
Copy link
Member

Zethson commented Jan 9, 2024

Description of feature

From https://www.nature.com/articles/s41467-020-17440-w

L1000 gene expression signatures were taken from either the LINCS Phase 2 data (GEO accession GSE70138, downloaded from http://amp.pharm.mssm.edu/Slicr) or LINCS Phase 1 data (GEO accession GSE92742, downloaded from clue.io). Phase 2 data were used when available (for the compounds trametinib, everolimus, and JQ1), while Phase 1 data were used for the remaining compounds (bortezomib, gemcitabine, and navitoclax). Comparisons were made using the average of the L1000 Level 5 gene expression signatures across all samples for a given drug and the average LFC values across all cell lines from the MIX-Seq experiment for that drug (24 h posttreatment).

This issues solely serves to not forget the idea. It might be revisited at a later time

@Zethson Zethson added the enhancement New feature or request label Jan 9, 2024
Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment
Labels
enhancement New feature or request
Projects
None yet
Development

No branches or pull requests

1 participant